IMPORTANT RESEARCH CARRIED OUT IN SERBIA: Four cities at the center of the trials, vaccination works!

Research conducted in Bor and Zajecar, that is, Smederevo and Pozarevac, shows that the curves began to separate when the epidemic began to heat up, and immunizations to show the effects, which, as the government notes, is a sign that the vaccine. “it works”.

As explained by the Government of Serbia, the analyzes have been carried out in parallel since the second half of January, when mass vaccination began in Serbia for geographically and demographically similar cities and close to each other.

The analysis showed that in Bor, where eight percent fewer people were vaccinated, in February there were half as many infected as in Zajecar, but in March the number of new infections in Bor began to grow dramatically, while in Zajecar it stagnated , which, as they point out, can only be attributed to vaccination.

In Bor, 17.2 percent of adult citizens were vaccinated, and in Zajecar 25.1 percent, and as the government says for Blic, that difference of eight percent is enough to draw parallels.

As regards the second pair of cities, in Požarevac and Smederevo, the curves practically overlapped in February and began to separate when the epidemic began to intensify, as well as the effects of vaccination.

Photo: SM

In Smederevo, 18.9 percent of citizens were vaccinated, while 25.6 percent of them received the vaccine in Pozarevac.

Since the beginning of March, when the effects of the vaccination began to be felt, the number of newly infected people in Pozarevac has increased by 50 percent and in Smederevo by 200 percent, according to the government.

The percentage of vaccinated in Serbia is between 15 and 30 percent.

According to government data, 2,521,863 doses of coronavirus vaccines have been administered in Serbia so far at 3pm yesterday, and 1,063,559 people have received the second dose.

Citizens of Serbia were vaccinated with the Russian Sputnik V, the Chinese Sinofarm, the vaccine developed by the American company Pfizer and the German company Biontek, as well as the vaccine from the British-Swedish company Astrazenek and the University of Oxford.